Compare Global X FTSE Southeast Asia ETF (ASEA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs TransMedics Group Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $21.53 | $150.42 |
52-Week Low | $16.86 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $21.45 with a modest 0.23% daily gain, showing bullish technical momentum with strong moving average support. The company has announced a $0.41 dividend for H1-2026, indicating management confidence in cash flow stability. Technical indicators show the stock is approaching resistance at $22 with strong trend momentum.
The stock presents a bullish technical setup near key resistance levels, though fundamental data remains limited. Dividend payments provide income appeal, but investors require updated financial metrics for comprehensive valuation assessment. Near-term price action will test the $22 resistance zone.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
